The role of surgery in the management of recurrent adrenocortical carcinoma
Open accessAbstract
CONTEXT: Surgery is the standard of care for localized adrenocortical carcinomas, but its role for recurrent disease is not well defined. OBJECTIVE: Our objective was to evaluate clinical outcome after surgery for recurrence. DESIGN: We conducted a retrospective analysis in 154 patients with first recurrence after initial radical resection from the German Adrenocortical Carcinoma Registry. MAIN OUTCOME MEASURES: We evaluated progression-free survival (PFS) and overall survival (OS) by Kaplan-Meier method and identified prognostic factors by Cox regression analysis. RESULT: A total of 101 patients underwent repeated surgery (radical resection, n = 78), and 99 received (additional) nonsurgical therapy. After a median of 6 (1-221) months, 144 patients (94%) experienced progression. Multivariate analysis adjusted for age, sex, tumor burden, time to first recurrence (TTFR), surgery for recurrence (including resection status), and additional therapy indicated that only two factors were significantly associated with shorter PFS [hazard ratio for progression: for TTFR ≤ 12 months, 1.8 (95% confidence interval = 1.3-2.6) vs. TTFR > 12 months; for macroscopically incomplete resection, 3.4 (1.5-7.9), and for no surgery, 3.4 (1.6-7.0) vs. microscopically complete (R0)-resection and OS [hazard ratio for death: for TTFR > 12 months, 3.1 (2.0-4.7) vs. TTFR ≤ 12 months; for macroscopically incomplete resection, 2.7 (1.1-6.9), and no surgery, 4.2 (1.8-9.6) vs. R0-resection]. Patients who had both TTFR over 12 months and R0-resection of recurrent tumors (n = 22) had the best prognosis (median PFS, 24 months; median OS, >60 months). CONCLUSIONS: The best predictors of prolonged survival after first recurrence are TTFR over 12 months and R0-resection. Our data suggest that patients with longer TTFR and tumors amenable to radical resection should be operated, whereas individualized treatment decisions are needed for patients with short TTFR or with not completely resectable tumors.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The number of organs involved by tumor at the time of the first metastasis is a predictor of survival.
“The number of organs involved by tumor at the time of the first metastasis is a predictor of survival (243, 265).”
From Adrenocortical carcinoma (2014) · cites this paper as [265]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Faßnacht, M., Terzolo, M., Allolio, B., Baudin, É., Haak, H. R., Berruti, A., Welin, S., Schade‐Brittinger, C., Lacroix, A., Jarząb, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 874 · see citing works
Self-citationAdjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759 · see citing works
Self-citationLuton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717 · see citing works
Fassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695 · see citing works
Self-citationIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543 · see citing works
Golden, S. H., Robinson, K. A., Saldanha, I., Anton, B., & Ladenson, P. W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2291 · Cited by 542 · see citing works
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493 · see citing works
Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors
Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1565 · Cited by 458 · see citing works
Self-citationAbiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435 · see citing works
Management of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421 · see citing works
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396 · see citing works
Self-citationSchulick, R. D., & Brennan, M. F. (1999) · Annals of Surgical Oncology · doi:10.1007/s10434-999-0719-7 · Cited by 366 · see citing works
An eleven-year experience with adrenocortical carcinoma.
Pommier, R. F., & Brennan, M. F. (1992) · PubMed · Cited by 332 · see citing works
Haak, H. R., Hermans, J., van de Velde, C., Lentjes, E. G. W. M., Goslings, B. M., Fleuren, G. J., & Krans, H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.183 · Cited by 329 · see citing works
Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization
Stojadinovic, A., Ghossein, R. A., Hoos, A., Nissan, A., Marshall, D., Dudas, M. E., Cordon‐Cardo, C., Jaques, D. P., & Brennan, M. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.941 · Cited by 312 · see citing works
Bellantone, R., Ferrante, A., Boscherini, M., Lombardi, C. P., Crucitti, P., Crucitti, F., Favia, G., Borrelli, D., Boffi, L., Capussotti, L., et al. (1997) · Surgery · doi:10.1016/s0039-6060(97)90229-4 · Cited by 210 · see citing works
Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma
Reibetanz, J., Jurowich, C., Erdogan, I., Nies, C., Rayes, N., Dralle, H., Behrend, M., Allolio, B., & Fassnacht, M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182367ac3 · Cited by 176 · see citing works
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial
Kroiss, M., Quinkler, M., Johanssen, S., van Erp, N. P., Lankheet, N., Pöllinger, A., Laubner, K., Strasburger, C. J., Hahner, S., Müller, H.-H., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1419 · Cited by 175 · see citing works
Hermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2676 · Cited by 173 · see citing works
Self-citationSperone, P., Ferrero, A., Daffara, F., Priola, A. M., Zaggia, B., Volante, M., Santini, D., Vincenzi, B., Badalamenti, G., Intrivici, C., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0281 · Cited by 167 · see citing works
Grubbs, E. G., Callender, G. G., Xing, Y., Perrier, N. D., Evans, D. B., Phan, A. T., & Lee, J. E. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0716-x · Cited by 158 · see citing works
Faßnacht, M., Johanssen, S., Fenske, W., Weismann, D., Agha, A., Beuschlein, F., Führer, D., Jurowich, C. F., Quinkler, M. O., Petersenn, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0803 · Cited by 156 · see citing works
Self-citationTreatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
Quinkler, M. O., Hahner, S., Wortmann, S., Johanssen, S., Adam, P., Ritte, C., Strasburger, C. J., Allolio, B., & Faßnacht, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2564 · Cited by 149 · see citing works
Self-citationBerruti, A., Sperone, P., Ferrero, A., Germano, A., Ardito, A., Priola, A. M., Francia, S. D., Volante, M., Daffara, F., Generali, D., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0918 · Cited by 138 · see citing works
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133 · see citing works
Self-citationOperative management for recurrent and metastatic adrenocortical carcinoma
Datrice, N., Langan, R. C., Ripley, R. T., Kemp, C. D., Steinberg, S. M., Wood, B. J., Libutti, S. K., Fojo, T., Schrump, D. S., & Avital, I. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.23015 · Cited by 99 · see citing works
Adrenocortical Carcinoma - Improving Patient Care by Establishing New Structures
Koschker, A., Faßnacht, M., Hahner, S., Weismann, D., & Allolio, B. (2006) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2006-923808 · Cited by 83 · see citing works
Self-citationAdrenocortical Carcinoma: Experience in 45 Patients
Barzon, L., Fallo, F., Sonino, N., Daniele, O., & Boscaro, M. (2009) · Oncology · doi:10.1159/000227608 · Cited by 83 · see citing works
Jensen, J. C. (1991) · Archives of Surgery · doi:10.1001/archsurg.1991.01410280059008 · Cited by 81 · see citing works
Adrenocortical Carcinoma in the United States: Treatment Utilization and Prognostic Factors
SCHTEINGART, D. E. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79396-5 · Cited by 62 · see citing works
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma
Francini, G., Petrioli, R., Gonnelli, S., Correale, P., Pozzessere, D., Marsili, S., Montagnani, A., Lucani, B., Rossi, S., Monaco, R. D., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 15 · see citing works
Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors
SCHTEINGART, D. E. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.05.017 · Cited by 11 · see citing works
SCHTEINGART, D. E. (2011) · Yearbook of Endocrinology · doi:10.1016/j.yend.2011.06.050 · Cited by 10 · see citing works
Fahey, T. J. (2011) · Yearbook of Surgery · doi:10.1016/j.ysur.2011.04.005 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892 · see citing works
Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma
Chortis, V., Bancos, I., Nijman, T., Gilligan, L. C., Taylor, A. E., Ronchi, C. L., O’Reilly, M. W., Schreiner, J., Asia, M., Riester, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz141 · Cited by 93 · see citing works
Self-citationKiseljak-Vassiliades, K., Bancos, I., Hamrahian, A., Habra, M. A., Vaidya, A., Levine, A. C., & Else, T. (2020) · Endocrine Practice · doi:10.4158/dscr-2020-0567 · Cited by 66 · see citing works
- Authors
- Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., Klose, S., Heidemeier, A., Brix, D., Fenske, W., Hahner, S., Reibetanz, J., Allolio, B., & Fassnacht, M.
- Affiliations
- University of Würzburg (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- Heinrich Heine University Düsseldorf (DE)
- LMU Klinikum (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University Hospital Magdeburg (DE)
- Universitätsklinikum Würzburg (DE)
- Corresponding author
- Fassnacht, Martin
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-01
- Volume
- 98
- Issue
- 1
- Pages
- 181-191
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2056952305
- Cited by
- 154
- References
- 35
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 9 · 2023: 8 · 2022: 11 · 2021: 12 · 2020: 12 · 2019: 13 · 2018: 16 · 2017: 12 · 2016: 12 · 2015: 21 · 2014: 8 · 2013: 11
- FWCI
- 13.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by-nc-nd)
- Funders
- Universitätsklinikum Regensburg
- Ludwig-Maximilians-Universität München
- Deutsche Krebshilfe
- Freie Universität Berlin
- Universitätsklinikum Köln
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- adrenocortical carcinoma, adrenalectomy, radical resection, time to recurrence, R0 resection, incomplete resection, progression-free survival, overall survival, prognostic factors, treatment decision-making, adjuvant therapy, resectability assessment, tumor burden
- MeSH terms
- Adolescent, Adrenal Cortex Neoplasms, Adrenalectomy, Adult, Aged, Female, Humans, Male, Middle Aged, Recurrence, Registries, Retrospective Studies, Survival Analysis, Treatment Outcome, Adrenocortical Carcinoma, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
